Polyrizon Ltd. (NASDAQ:PLRZ) saw its stock rise 10% on Friday after announcing that NASARIX Allergy Blocker, a drug-free mucoadhesive nasal spray, met all predetermined acceptance criteria across a formal biocompatibility evaluation program.
The company described the testing regimen as comprehensive and developed in alignment with internationally recognized frameworks for biological safety assessment of medical devices, including the ISO 10993 series, applicable U.S. Food and Drug Administration guidance, and relevant European regulatory requirements. Polyrizon is identified in its materials as a development-stage biotechnology company.
The completed program assessed several core biological safety endpoints. Those included cytotoxicity, sensitization, irritation, material-mediated pyrogenicity, and acute systemic toxicity. In addition, long-term systemic toxicity was evaluated through a toxicological risk assessment following ISO 10993-17 methodology. Polyrizon said the biocompatibility work was based on the final NASARIX product configuration.
Supportive activities for the evaluation extended beyond the finished product to include analysis of formulation components, manufacturing processes, packaging materials, and intended patient exposure, the company said. Together, these elements formed the basis for concluding that the device met the pre-established safety thresholds used in the program.
In a company statement, Tomer Izraeli, chief executive of Polyrizon, said achieving positive results across all required biological safety assessments is a significant milestone in the NASARIX development program and bolsters the product's biocompatibility safety profile as Polyrizon advances its clinical and regulatory pathway.
Polyrizon noted that the biocompatibility evaluation program was structured under a risk-management framework consistent with ISO 10993-1 and ISO 14971. The company characterized the successful completion of the program as a step toward potential commercialization of NASARIX as a nasal barrier technology for people with seasonal allergies.
Context and implications
By designing the evaluation in accordance with the ISO 10993 series, FDA guidance, and European requirements, Polyrizon aligned the safety assessment with commonly referenced regulatory expectations for medical device biocompatibility. The company framed the results as supportive for NASARIX's continued clinical development and regulatory interactions, and as progress toward potential market introduction.
Financial market reaction to the announcement was immediate, with a single-day share increase of 10% on the news, reflecting investor interest in milestones that may de-risk future regulatory steps.